New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term disability in multiple sclerosis (MS) patients.
Early intervention in pediatric-onset MS can lead to improved long-term outcomes
- Post author:
- Post published:September 18, 2024
- Post category:uncategorized